Business Description
Intra-Cellular Therapies Inc
NAICS : 325412
SIC : 2834
ISIN : BRI2TCBDR009
Share Class Description:
BSP:I2TC34: BRDRCompare
Compare
Traded in other countries / regions
ITCI.USAITCI.MexicoI2TC34.Brazil23I.Germany IPO Date
2023-07-24Description
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 56.84 | |||||
| Equity-to-Asset | 0.86 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 29.94 | |||||
| Beneish M-Score | 90.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 147 | |||||
| 3-Year EBITDA Growth Rate | 20.3 | |||||
| 3-Year EPS without NRI Growth Rate | 23.3 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -9.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 44.74 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.25 | |||||
| 9-Day RSI | 61.09 | |||||
| 14-Day RSI | 72.94 | |||||
| 6-1 Month Momentum % | 37.04 | |||||
| 12-1 Month Momentum % | 68.3 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.66 | |||||
| Quick Ratio | 7.51 | |||||
| Cash Ratio | 6.06 | |||||
| Days Inventory | 176.4 | |||||
| Days Sales Outstanding | 76.14 | |||||
| Days Payable | 94.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | 0.01 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 92.29 | |||||
| Operating Margin % | -19.85 | |||||
| Net Margin % | -14.1 | |||||
| FCF Margin % | -10.11 | |||||
| ROE % | -10.58 | |||||
| ROA % | -8.93 | |||||
| ROIC % | -77.81 | |||||
| ROC (Joel Greenblatt) % | -120.12 | |||||
| ROCE % | -14.66 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 38.77 | |||||
| PS Ratio | 14.16 | |||||
| PB Ratio | 7.96 | |||||
| Price-to-Tangible-Book | 7.96 | |||||
| EV-to-EBIT | -66.84 | |||||
| EV-to-Forward-EBIT | 178.7 | |||||
| EV-to-EBITDA | -67.13 | |||||
| EV-to-Forward-EBITDA | -705.81 | |||||
| EV-to-Revenue | 13.27 | |||||
| EV-to-Forward-Revenue | 8.4 | |||||
| EV-to-FCF | -130.77 | |||||
| Price-to-Net-Current-Asset-Value | 8.35 | |||||
| Price-to-Net-Cash | 11.03 | |||||
| Earnings Yield (Greenblatt) % | -1.57 | |||||
| FCF Yield % | -0.69 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Intra-Cellular Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil R$) | 3,204.287 | ||
| EPS (TTM) (R$) | -0.753 | ||
| Beta | 0 | ||
| Volatility % | 36.92 | ||
| 14-Day RSI | 72.94 | ||
| 14-Day ATR (R$) | 0.163445 | ||
| 20-Day SMA (R$) | 84.588 | ||
| 12-1 Month Momentum % | 68.3 | ||
| 52-Week Range (R$) | 49.53 - 85.98 | ||
| Shares Outstanding (Mil) | 106.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Intra-Cellular Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Intra-Cellular Therapies Inc Stock Events
| Event | Date | Price(R$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Intra-Cellular Therapies Inc Frequently Asked Questions
What is Intra-Cellular Therapies Inc(BSP:I2TC34)'s stock price today?
The current price of BSP:I2TC34 is R$84.24. The 52 week high of BSP:I2TC34 is R$85.98 and 52 week low is R$49.53.
When is next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34)?
The next earnings date of Intra-Cellular Therapies Inc(BSP:I2TC34) is 2025-02-21 Est..
Does Intra-Cellular Therapies Inc(BSP:I2TC34) pay dividends? If so, how much?
Intra-Cellular Therapies Inc(BSP:I2TC34) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers